Company intelligence / Profile preview

EVE Medical Systems Ltd.

Ownership: Private
Development stage: Clinical

Overview

The company has developed a proprietary diagnostic and therapeutic system for identifying sensitivity to female sex hormones using a skin test panel. Women identified as sensitive are treated with intradermal hormone injections to induce tolerance. Two Phase 2 clinical trials have been conducted targeting severe PMS and unexplained recurrent pregnancy loss, but no published results or approvals yet.

Therapeutic areas: Women's Health
Modalities: Immunomodulators (hormone desensitization therapy)
Industry: Biotech

Drug pipeline

1 asset

EVE-PMS Diagnostic Skin Test Panel and Solvent

Unknown

Beyond the preview

Go deeper on EVE Medical Systems Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVE Medical Systems Ltd..

Explore the full profile